The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | REZILIENT1: zipalertinib, a novel EGFR TKI, in NSCLC with ex20ins mutations
Antonio Passaro, MD, PhD, Istituto Europeo di Oncologia, Milan, Italy, discusses data from the Phase IIb REZILIENT1 study (NCT04036682) of zipalertinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with EGFR exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC) who progressed after amivantamab. Zipalertinib showed promising anti-tumor activity and a manageable safety profile in heavily pretreated patients, offering a potential new option for those with amivantamab-resistant disease, along with TKIs such as firmonertinib and sunvozertinib. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
